News Column

Data on Gene Therapy Detailed by Researchers at Science Institute

February 13, 2014

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Biotechnology. According to news reporting out of Brussels, Belgium, by NewsRx editors, research stated, "The majority of humans have been infected with Herpes Simplex Virus Type 1 (HSV-1) and harbor its viral DNA in the latent form within neurons for lifetime. This, combined with the absence of serious adverse effects due to HSV-1 derived vectors in clinical trials so far, highlight the potential to use this virus to develop neuronal gene transfer vectors which are transparent to the host, allowing the effects of the transgene to act without interference from the transfer system eg., for functional genomics in basic neuroscience or gene therapy of neurological disorders."

Our news journalists obtained a quote from the research from Science Institute, "On the other hand, other HSV-1 derived vectors which also have a promising perspective in the clinic, are designed to have enhanced cytotoxicity in certain cell types, as in the case of oncolytic vectors. Understanding virus-host interactions is fundamental not only to the success of these gene therapy vectors but also with respect to identifying and minimizing biohazards associated with their use."

According to the news editors, the research concluded: "In this review we discuss characteristics of HSV-1 and gene therapy vectors derived from this virus which are useful to consider in the context of biosafety risk assessment and risk management."

For more information on this research see: Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1. Current Gene Therapy, 2013;13(6):478-491. Current Gene Therapy can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers -; Current Gene Therapy -

Our news journalists report that additional information may be obtained by contacting F. Lim, Sci Inst Public Hlth WIV ISP, Biosafety & Biotechnol Unit, B-1050 Brussels, Belgium. Additional authors for this research include H. Khalique, M. Ventosa and A. Baldo (see also Biotechnology).

Keywords for this news article include: Biotechnology, Europe, Belgium, Brussels, Genetics, Virology, DNA Viruses, Gene Therapy, Bioengineering, Viral Skin Diseases, DNA Virus Infections, Herpes Simplex Virus, Herpesviridae Infections, Clinical Trials and Studies, Herpes Simplex Encephalitis

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Gene Therapy Weekly

Story Tools